SuperGen to Present at Noble Financial Capital Markets Equity Conference on May 17th

DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that Michael V. McCullar, Ph.D., senior vice president, strategy and discovery operations, will present at Noble Financial Capital Markets’ Seventh Annual Equity Conference on Tuesday, May 17th in Florida.

SuperGen's presentation will begin at 10:30 a.m. ET. A live audio and high-definition video webcast of the presentation will be available in the Investor Events section of the Company's website at www.supergen.com. SuperGen recommends registering at least ten minutes before the presentation to download the free presentation viewer program. The webcast will be archived for 90 days.

About SuperGen

SuperGen is a pharmaceutical company dedicated to discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. On April 6, 2011, SuperGen entered into a definitive merger agreement to acquire Astex Therapeutics Limited, a UK based biotechnology company. The transaction is subject to customary regulatory, legal and shareholder approvals. For more information about SuperGen, please visit http://www.supergen.com.



CONTACT:

SuperGen, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Business Development
[email protected]
Susanna Chau, 925-560-2845
Manager
Investor Relations
[email protected]

KEYWORDS:   United States  North America  California  Florida

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.